eliglustat治疗1型戈谢病8年后的结局:2期试验最终结果
这项2期试验及其扩展研究纳入26例既往未治疗的1型戈谢病成人患者,接受 eliglustat 酒石酸盐50或100mg(相当于 eliglustat 42或84mg)每日两次治疗8年,19例完成试验。8年后脾脏和肝脏体积分别平均缩小69%和34%,血红蛋白和血小板计数分别平均增加2.2 g/dL和113%,所有患者达到长期酶替代治疗设定的4项治疗目标中至少3项。
要点
- 8年 eliglustat 治疗后脾脏和肝脏体积分别平均缩小69%和34%。
- 血红蛋白平均增加2.2 g/dL,血小板计数平均增加113%。
- 所有患者达到长期酶替代治疗4项治疗目标中至少3项。
核心结论
- 8年 eliglustat 治疗在1型戈谢病成人患者中显示出临床有意义的改善,且在最严重受累患者中改善幅度最大。
研究设计与样本
- 2期试验及其扩展研究(NCT00358150),纳入26例既往未治疗的1型戈谢病成人患者,均有脾肿大伴血小板减少和/或贫血,接受 eliglustat 酒石酸盐50或100mg(相当于 eliglustat 42或84mg)每日两次治疗8年,19例完成试验。
主要发现
- 8年 eliglustat 治疗后,脾脏和肝脏体积分别平均缩小69%和34%。
- 血红蛋白浓度和血小板计数分别平均增加2.2 g/dL和113%。
- 所有患者达到长期酶替代治疗设定的4项治疗目标中至少3项。
- 严重脾肿大(n=6)、中重度贫血(n=6)或严重血小板减少(n=8)患者的平均最终值与基线病情较轻患者相似,且处于长期治疗目标阈值内。
- 生物标志物自基线中位百分比变化:壳三糖苷酶-91%、CCL18 -87%、葡萄糖鞘氨醇-92%、血浆葡萄糖神经酰胺-80%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eliglustat is a first-line oral therapy for adults with Gaucher disease type 1 (GD1) and poor, intermediate or extensive CYP2D6-metabolizer phenotypes (>90% of patients). We report the final results of a Phase 2 trial and extension (NCT00358150) in previously untreated adult GD1 patients who had splenomegaly with thrombocytopenia and/or anemia and received 50 or 100 mg eliglustat tartrate (equivalent to 42 or 84 mg eliglustat) twice daily for 8 years. In total, 19 of 26 patients completed the trial. After 8 years of eliglustat, mean spleen and liver volumes decreased by 69% and 34%, respectively. Mean hemoglobin concentration and platelet count increased by 2.2 g/dL and 113%, respectively. All patients met at least 3 of 4 therapeutic goals established for patients on long-term enzyme replacement therapy. Mean final values for patients with severe splenomegaly (n = 6), moderate-to-severe anemia (n = 6), or severe thrombocytopenia (n = 8) were similar to patients with milder disease at baseline and within long-term therapeutic goal thresholds. Biomarker median percent changes from baseline were -91% for chitotriosidase, -87% for CCL18, -92% for glucosylsphingosine, and -80% for plasma glucosylceramide. Mean lumbar spine T-score increased by 0.96, moving from the osteopenic to the normal range. Mean quality-of-life scores, mostly below normal at baseline, moved into ranges seen in healthy adults. Eliglustat was well-tolerated; 98% of adverse events were mild or moderate and 94% were considered unrelated to treatment. Clinically meaningful improvements in all parameters continued or were maintained over 8 years, with the largest margins of improvement seen in the most severely affected patients.
引用
- Lukina E, Watman N, Dragosky M, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. Am J Hematol. 2018. PMID: 30264864. doi:10.1002/ajh.25300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。